Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Response Predictors in MDD
NCT03207438Phase 4Completed
- Sponsor
- University of Saskatchewan
- Start
- Apr 2006
- Primary completion
- Jul 2007
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial of quetiapine (extended-release tablet, brand name: Bipresso) in major depressive disorder (MDD) (4 arms), sponsored by University of Saskatchewan. Primary endpoints: Montgomery-Asberg Depression Rating Scale Response Rate at 6 weeks and Modified Montgomery-Asberg Depression Rating Scale Response Rate at 6 weeks. Started Apr 2006; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03207438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207438.